Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer
氟维司群、帕博西尼和厄达替尼(一种泛FGFR酪氨酸激酶抑制剂)治疗HR+/HER2-转移性乳腺癌的Ib期试验
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3803
Gonzalez-Ericsson, Paula I; Unni, Nisha; Jhaveri, Komal; Stringer-Reasor, Erica; Liu, Qi; Wang, Yu; Sanchez, Violeta; Garcia, Guadalupe; Sanders, Melinda E; Lehmann, Brian D; Balko, Justin M; Park, Ben; Rexer, Brent N; Mayer, Ingrid A; Arteaga, Carlos L